Abstract
BackgroundTofacitinib is an oral JAK inhibitor for the treatment of RA. Limited real-world data exist comparing tofacitinib with biologic DMARDs (bDMARDs) in biologic-experienced (BE) RA patients (pts).ObjectivesTo compare pt characteristics,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have